Atara Biotherapeutics (NASDAQ:ATRA) Releases Quarterly Earnings Results, Misses Expectations By $1.54 EPS

Atara Biotherapeutics (NASDAQ:ATRA) posted its earnings results on Monday. The biotechnology company reported ($3.10) EPS for the quarter, missing analysts’ consensus estimates of ($1.56) by ($1.54), Yahoo Finance reports. The firm had revenue of $28.64 million during the quarter, compared to analysts’ expectations of $48.30 million.

Atara Biotherapeutics Stock Down 1.5 %

Shares of NASDAQ ATRA traded down $0.12 during midday trading on Tuesday, hitting $7.65. The stock had a trading volume of 9,484 shares, compared to its average volume of 91,490. Atara Biotherapeutics has a 1 year low of $4.96 and a 1 year high of $52.25. The company has a market capitalization of $36.85 million, a PE ratio of -0.14 and a beta of 0.52. The stock has a 50 day simple moving average of $9.99 and a 200-day simple moving average of $15.01.

Insider Buying and Selling

In other Atara Biotherapeutics news, EVP Anhco Nguyen sold 1,715 shares of Atara Biotherapeutics stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $15.50, for a total transaction of $26,582.50. Following the sale, the executive vice president now owns 35,939 shares of the company’s stock, valued at approximately $557,054.50. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO Pascal Touchon sold 3,260 shares of Atara Biotherapeutics stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $15.50, for a total transaction of $50,530.00. Following the transaction, the chief executive officer now owns 73,165 shares in the company, valued at $1,134,057.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Anhco Nguyen sold 1,715 shares of the business’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $15.50, for a total value of $26,582.50. Following the transaction, the executive vice president now directly owns 35,939 shares in the company, valued at approximately $557,054.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 6,120 shares of company stock worth $94,860. 3.70% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have recently weighed in on ATRA shares. HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a research note on Wednesday, May 22nd. StockNews.com started coverage on shares of Atara Biotherapeutics in a research report on Wednesday, June 26th. They set a “hold” rating for the company. Finally, The Goldman Sachs Group decreased their price objective on shares of Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating on the stock in a report on Wednesday, July 17th. One analyst has rated the stock with a sell rating and four have issued a hold rating to the stock. According to MarketBeat.com, Atara Biotherapeutics has an average rating of “Hold” and an average target price of $355.50.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.